A study in healthy men to test how well different doses of BI 3776528 are tolerated

2024-515222-92-00 Protocol 1526-0001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 8 Jan 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol 1526-0001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 172
Countries 1
Sites 1

Healthy volunteer trial

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Not possible to specify
Trial duration
8 Jan 2025 → ongoing
Decision date (initial)
2024-11-27
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-515222-92-00
WHO UTN
U1111-1307-8288

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteer trial

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 172 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruiting
Charite Research Organisation GmbH
Charité Universitätsmedizin Berlin, Chariteplatz 1, Mitte, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-01-08 2025-01-23

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-27 Germany Acceptable
2024-11-25
2024-11-27
2 SUBSTANTIAL MODIFICATION SM-1 2025-07-01 Germany Acceptable
2025-07-22
2025-07-24
3 SUBSTANTIAL MODIFICATION SM-2 2025-10-14 Germany Acceptable
2025-11-04
2025-11-05